Trails Edge Capital Partners, LP
Trails Edge Capital Partners, LP reported 38 holdings worth US$696M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Trails Edge Capital Partners, LP reported 38 holdings worth US$696M as of Sep 30, 2026. Largest: LB Pharmaceuticals Inc, BioMarin Pharmaceutical Inc. and Nurix Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 38
- Value as reported
- US$696M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| LB Pharmaceuticals Inc | 1.15M | US$44.1M | 6.3% |
| BioMarin Pharmaceutical Inc. | 667K | US$40M | 5.8% |
| Nurix Therapeutics, Inc. | 1.57M | US$37.3M | 5.4% |
| Obsidian Therapeutics, Inc. | 2.5M | US$34.3M | 4.9% |
| Immunocore Holdings plc | 1.06M | US$32.2M | 4.6% |
| 4D Molecular Therapeutics, Inc. | 2.23M | US$31.9M | 4.6% |
| Design Therapeutics, Inc. | 2.5M | US$31.4M | 4.5% |
| Cytokinetics, Incorporated | 470K | US$31M | 4.5% |
| First Tracks Biotherapeutics, Inc. | 814K | US$28.8M | 4.1% |
| Sensei Biotherapeutics, Inc. | 942K | US$28M | 4.0% |
| Tango Therapeutics, Inc. | 1.1M | US$27.4M | 3.9% |
| Neurogene Inc. | 965K | US$26.8M | 3.9% |
| Celldex Therapeutics, Inc. | 765K | US$24.8M | 3.6% |
| Avalo Therapeutics, Inc. | 1.5M | US$23M | 3.3% |
| Contineum Therapeutics, Inc. | 1.69M | US$22.7M | 3.3% |
| Tyra Biosciences, Inc. | 1M | US$21.9M | 3.1% |
| Inhibikase Therapeutics, Inc. | 9.11M | US$18.7M | 2.7% |
| Inhibrx Biosciences, Inc. | 170K | US$17M | 2.4% |
| Xenon Pharmaceuticals Inc. | 400K | US$14.9M | 2.1% |
| CAMP4 Therapeutics Corporation | 3.63M | US$14.6M | 2.1% |
| Altimmune, Inc. | 4.23M | US$12.1M | 1.7% |
| Opus Genetics, Inc. | 2.41M | US$11.7M | 1.7% |
| Kailera Therapeutics, Inc. | 943K | US$10.8M | 1.5% |
| Inventiva SA | 2.66M | US$9.81M | 1.4% |
| Entrada Therapeutics, Inc. | 1.43M | US$9.07M | 1.3% |
| Aura Biosciences, Inc. | 1.44M | US$9.06M | 1.3% |
| Research Alliance Corporation III | 823K | US$8.91M | 1.3% |
| X4 Pharmaceuticals, Inc. | 2.57M | US$7.46M | 1.1% |
| Century Therapeutics, Inc. | 4.13M | US$7.07M | 1.0% |
| ProMIS Neurosciences Inc. | 557K | US$6.04M | 0.87% |
| Research Alliance Corporation IV | 500K | US$6M | 0.86% |
| ImageneBio, Inc. | 1.09M | US$5.01M | 0.72% |
| Minerva Neurosciences, Inc | 1.42M | US$4.75M | 0.68% |
| TCGX Acquisition Corp. | 250K | US$3.13M | 0.45% |
| vTv Therapeutics Inc. | 76,989 | US$2.37M | 0.34% |
| OnKure Therapeutics, Inc. | 620K | US$1.69M | 0.24% |
| Insmed Incorporated | 0 | US$0 | 0.00% |
| Mirum Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Revolution Medicines, Inc. | 0 | US$0 | 0.00% |
| Syndax Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Forte Biosciences, Inc. | 0 | US$0 | 0.00% |
| Incyte Corporation | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related